Main Article Content
Tuberculosis had become one of the top 10 fatal diseases in the world in 2015. The WHO's current recommendation is to provide an injection daily for ³ 8 months, with a total treatment duration of ³ 20 months. The lack of effective and dependable medications for the treatment of MDR TB threatensthe achievement of national and global TB treatment target programs. Tuberculosis is an infectious disease with a high rate of morbidity and mortality. Tuberculosis therapy has started to encounter resistance. Nevertheless, current resistance therapy administration has a high risk and low therapeutic success rate. Delamanid, as a newly considered medication, has shown promising efficacy and benefits in reducing the failure rate of tuberculosis therapy resistance.